Outputs (4)

Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts (2022)
Journal Article
Sharpe, B. P., Hayden, A., Manousopoulou, A., Cowie, A., Walker, R. C., Harrington, J., Izadi, F., Breininger, S. P., Gibson, J., Pickering, O., Jaynes, E., Kyle, E., Saunders, J. H., Parsons, S. L., Ritchie, A. A., Clarke, P. A., Collier, P., Mongan, N. P., Bates, D. O., Yacqub-Usman, K., …Underwood, T. J. (2022). Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts. Cell Reports Medicine, 3(6), Article 100541. https://doi.org/10.1016/j.xcrm.2022.100541

The chemotherapy resistance of esophageal adenocarcinomas (EACs) is underpinned by cancer cell extrinsic mechanisms of the tumor microenvironment (TME). We demonstrate that, by targeting the tumor-promoting functions of the predominant TME cell type,... Read More about Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts.

Targeting hypoxia regulated sodium driven bicarbonate transporters reduces triple negative breast cancer metastasis (2022)
Journal Article
Harris, A. L., Clarke, P. A., Carroll, C. P., Bolland, H., Vancauwenberghe, E., Collier, P., Ritchie, A. A., Grabowska, A. M., & McIntyre, A. (2022). Targeting hypoxia regulated sodium driven bicarbonate transporters reduces triple negative breast cancer metastasis. Neoplasia, 25, 41-52. https://doi.org/10.1016/j.neo.2022.01.003

Regions of low oxygen (hypoxia) are found in >50% of breast tumours, most frequently in the more aggressive triple negative breast cancer subtype (TNBC). Metastasis is the cause of 90% of breast cancer patient deaths. Regions of tumour hypoxia tend t... Read More about Targeting hypoxia regulated sodium driven bicarbonate transporters reduces triple negative breast cancer metastasis.

A 3D Heterotypic Breast Cancer Model Demonstrates a Role for Mesenchymal Stem Cells in Driving a Proliferative and Invasive Phenotype (2020)
Journal Article
Pal, A., Ashworth, J. C., Collier, P., Probert, C., Jones, S., Leza, E. P., Meakin, M. L., A. Ritchie, A., Onion, D., Clarke, P. A., Allegrucci, C., & Grabowska, A. M. (2020). A 3D Heterotypic Breast Cancer Model Demonstrates a Role for Mesenchymal Stem Cells in Driving a Proliferative and Invasive Phenotype. Cancers, 12(8), Article 2290. https://doi.org/10.3390/cancers12082290

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance (2016)
Journal Article
Secrier, M., Li, X., de Silva, N., Eldridge, M. D., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O'Donovan, M., Miremadi, A., Yang, T.-P., Bower, L., Chettouh, H., Crawte, J., Galeano-Dalmau, N., Grabowska, A., Saunders, J., Underwood, T., Waddell, N., Barbour, A. P., …Grimmond, S. M. (2016). Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nature Genetics, 48(10), https://doi.org/10.1038/ng.3659

Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been disappointing owing to a lack of robust stratification methods. Whole-genome sequencing (WGS) analysis of 129 cases demonstrated that this is a heterog... Read More about Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.